| Development of potent monoclonal antibody auristatin conjugates for cancer therapy SO Doronina, BE Toki, MY Torgov, BA Mendelsohn, CG Cerveny, ... Nature biotechnology 21 (7), 778-784, 2003 | 1490 | 2003 |
| Arming antibodies: prospects and challenges for immunoconjugates AM Wu, PD Senter Nature biotechnology 23 (9), 1137-1146, 2005 | 1417 | 2005 |
| Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate KJ Hamblett, PD Senter, DF Chace, MMC Sun, J Lenox, CG Cerveny, ... Clinical cancer research 10 (20), 7063-7070, 2004 | 1316 | 2004 |
| cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity JA Francisco, CG Cerveny, DL Meyer, BJ Mixan, K Klussman, DF Chace, ... Blood 102 (4), 1458-1465, 2003 | 1105 | 2003 |
| Monomethylvaline compounds capable of conjugation to ligands SO Doronina, PD Senter, BE Toki US Patent 7,498,298, 2009 | 917 | 2009 |
| The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma PD Senter, EL Sievers Nature biotechnology 30 (7), 631-637, 2012 | 880 | 2012 |
| Antibody-drug conjugates in cancer therapy EL Sievers, PD Senter Annual review of medicine 64, 15-29, 2013 | 874 | 2013 |
| Antibody–drug conjugates: targeted drug delivery for cancer SC Alley, NM Okeley, PD Senter Current opinion in chemical biology 14 (4), 529-537, 2010 | 818 | 2010 |
| Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells PD Senter, MG Saulnier, JP Brown, DE Kerr US Patent 4,975,278, 1990 | 636 | 1990 |
| Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity SO Doronina, BA Mendelsohn, TD Bovee, CG Cerveny, SC Alley, ... Bioconjugate chemistry 17 (1), 114-124, 2006 | 600 | 2006 |
| Contribution of linker stability to the activities of anticancer immunoconjugates SC Alley, DR Benjamin, SC Jeffrey, NM Okeley, DL Meyer, RJ Sanderson, ... Bioconjugate chemistry 19 (3), 759-765, 2008 | 570 | 2008 |
| Potent antibody drug conjugates for cancer therapy PD Senter Current opinion in chemical biology 13 (3), 235-244, 2009 | 524 | 2009 |
| Efficient cancer therapy with a nanobody-based conjugate V Cortez-Retamozo, N Backmann, PD Senter, U Wernery, P De Baetselier, ... Cancer research 64 (8), 2853-2857, 2004 | 524 | 2004 |
| Antibody-drug conjugates for cancer therapy PJ Carter, PD Senter The Cancer Journal 14 (3), 154-169, 2008 | 516 | 2008 |
| Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease PD Senter, SO Doronina, BE Toki US Patent 7,659,241, 2010 | 474 | 2010 |
| Chemotherapy delivery issues in central nervous system malignancy: a reality check LL Muldoon, C Soussain, K Jahnke, C Johanson, T Siegal, QR Smith, ... Journal of clinical oncology 25 (16), 2295-2305, 2007 | 468 | 2007 |
| Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index RP Lyon, TD Bovee, SO Doronina, PJ Burke, JH Hunter, HD Neff-LaFord, ... Nature biotechnology 33 (7), 733-735, 2015 | 455 | 2015 |
| Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates RP Lyon, JR Setter, TD Bovee, SO Doronina, JH Hunter, ME Anderson, ... Nature biotechnology 32 (10), 1059-1062, 2014 | 449 | 2014 |
| Reduction− alkylation strategies for the modification of specific monoclonal antibody disulfides MMC Sun, KS Beam, CG Cerveny, KJ Hamblett, RS Blackmore, ... Bioconjugate chemistry 16 (5), 1282-1290, 2005 | 449 | 2005 |
| Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate NM Okeley, JB Miyamoto, X Zhang, RJ Sanderson, DR Benjamin, ... Clinical Cancer Research 16 (3), 888-897, 2010 | 424 | 2010 |
